Sanofi Appeal Puts Hospira's Generic Eloxatin On Hold

Law360, New York (August 17, 2009, 2:29 PM EDT) -- Hospira Inc.'s efforts to tap into the $1.4 billion annual U.S. market for Sanofi-Aventis' cancer treatment Eloxatin have hit a snag now that the U.S. Food and Drug Administration has suspended its approval of Hospira's generics because of a federal appeals court's order in litigation Sanofi-Aventis brought against the FDA.

In an Aug. 14 filing with the U.S. Securities and Exchange Commission, Hospira said the FDA had suspended the abbreviated new drug application approval for its generic oxaliplatin injection, three days after announcing that the FDA...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.